Nasdaq · Biotech stocks database
JAZZ — Jazz Pharmaceuticals plc ☆
JAZZ (Jazz Pharmaceuticals plc) stock: $244.32, $15.68B market cap, $2.04B cash, $19.22B EV, $17.06B fully diluted market cap. Lead program: Cannabidiol (Lennox Gastaut Syndrome), Phase 4. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
Source: 10-K FY2025 via SEC EDGAR
Enterprise value
$19,215.6M
Balance sheet
Cash $2,036.4M Debt $5,569.4M Net cash -$3,533.0M Enterprise value $19,215.6M Basic shares 64.2M shares Fully diluted shares 69.8M shares Fully diluted market cap $17,057.1M Cash per share $31.72 Quarterly burn +$415.7M generated
Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.
Share structure
Cap table as of 2026-06-30.
Price history Loading JAZZ daily closes…
Loading price history…
Next catalyst Zanidatamab · Nov 11 - Dec 23 Now · Phase 3 · Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal AdenocarcinomaAll upcoming catalysts (+20 more) →
Recently reported Zanidatamab Positive · 2026-08-31
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Nov 11 - Dec 23 Now Zanidatamab Phase 3 Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma — Feb 11 - Mar 25 in 13 wks Zanidatamab Phase 2 Breast Cancer; Gastric Cancer; Esophageal Cancer — GUIDED Est. Apr 1, 2027 in 7 wks guidance midpoint
dordaviprone (Modeyso)Phase 3 ACTION
Phase 3 Not disclosed 1H27 Apr 10 - May 22 in 5 mo JZP269 Phase 1 Healthy Participants — Jul 12 - Aug 23 in 8 mo ONC206 Phase 1 Diffuse Midline Glioma (DMG); Glioblastoma; Recurrent Ependymoma — Jan 10 - Feb 21 in 14 mo CBD-OS Phase 1 Focal Seizures — Jan 11 - Feb 22 in 14 mo JZP898 Phase 1 Advanced Solid Tumor; Metastatic Solid Tumor — Feb 3 - Mar 16 in 15 mo Xywav Phase 3 Narcolepsy; Idiopathic Hypersomnia — Feb 12 - Mar 25 in 15 mo Zanidatamab Phase 2 HER2-positive Breast Cancer; Breast Cancer 3Q26 Mar 10 - Apr 21 in 16 mo Lurbinectedin Phase 2 Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma; Ewing Sarcoma — Mar 13 - Apr 24 in 16 mo Lurbinectedin Phase 2 Extensive-stage Small-cell Lung Cancer — Apr 24 - Jun 5 in 18 mo Zanidatamab Phase 2 Non-Small Cell Lung Cancer; Sarcoma; Head &Amp; Neck Cancer — May 13 - Jun 24 in 18 mo JZP815 Phase 1 Advanced Cancer; Metastatic Cancer; Solid Tumor — Jun 9 - Jul 21 in 19 mo Zanidatamab Phase 3 Metastatic HER2-positive Breast Cancer 3Q26 Jul 13 - Aug 24 in 20 mo Dordaviprone (ONC201) Phase 3 H3 K27M; Glioma — Sep 12 - Oct 24 in 22 mo JZP926 capsule Phase 3 Juvenile Myoclonic Epilepsy — Oct 13 - Nov 24 in 23 mo Everolimus Phase 3 Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Diffuse Midline Glioma, H3K27-altered — Dec 6, 2028 - Jan 17, 2029 in 25 mo JZP3507 Phase 2 Meningioma — Jan 12 - Feb 23 in 26 mo Zanidatamab Phase 3 Biliary Tract Cancer — Jan 26 - Mar 9 in 27 mo ONC206 Phase 2 Advanced Pheochromocytoma and Paraganglioma; PCPG — Apr 12 - May 24 in 29 mo Zanidatamab Phase 2 Gastroesophageal Adenocarcinoma; First Line Therapy; HER2 + Gastric Cancer 3Q26 Oct 16 - Nov 27 in 36 mo CBD-OS Phase 3 Developmental and Epileptic Encephalopathy (DEE) —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets Xywav
Approved · Active Modality: calcium, magnesium, potassium, and sodium oxybates oral solution
Indications narcolepsy (cataplexy or excessive daytime sleepiness) (Approved) idiopathic hypersomnia (adults) (Approved) Status note Commercial product.
Xyrem
Approved · Active Modality: sodium oxybate oral solution
Target GABA-B receptor
Indications Narcolepsy (cataplexy; excessive daytime sleepiness) (Approved) Status note Commercial product; subject to 505(b)(2) notices from Tris Pharma.
Epidiolex
Approved · Active Modality: cannabidiol oral solution
Aliases Epidyolex
Partnerships Nippon Zoki (Japan)
Indications seizures associated with LGS, DS, or TSC (Approved) focal-onset seizures (Phase 1) juvenile myoclonic epilepsy (Phase 2/3) Status note Commercial product; additional indications in development; cannabidiol capsule NDA submitted mid-2026.
Ziihera
Approved · Active Modality: bispecific HER2-directed antibody
Aliases zanidatamab
Target HER2
Partnerships Zymeworks (exclusive license, US/Europe/Japan and other territories)
Indications HER2-positive biliary tract cancer (Approved) HER2-positive gastroesophageal adenocarcinoma, first-line (Phase 3) Status note Accelerated approval November 2024 for HER2-positive BTC; confirmatory Phase 3 HERIZON-BTC-302 ongoing.
Modeyso
Approved · Active Modality: small molecule
Aliases dordaviprone
Target ClpP; DRD2
Partnerships Chimerix (acquired April 2025)
Indications H3 K27M-mutant diffuse midline glioma (Approved) Status note Accelerated approval August 2025; confirmatory Phase 3 ACTION trial ongoing.
Zepzelca
Approved · Active
Aliases lurbinectedin
Target DNA guanine residues
Partnerships PharmaMar (US rights)
Indications small cell lung cancer (Approved) Status note LAGOON Phase 3 did not meet its primary endpoint; labeling supplement planned Q3 2026 to remove the second-line indication.
Rylaze
Approved · Active Modality: asparaginase erwinia chrysanthemi (recombinant)
Aliases Enrylaze
Indications acute lymphoblastic leukemia (ALL) (Approved) lymphoblastic lymphoma (LBL) (Approved) Status note Commercial product.
Defitelio
Approved · Active Modality: defibrotide sodium
Target Vascular endothelium (antithrombotic/profibrinolytic)
Indications Hepatic veno-occlusive disease (VOD/SOS) with renal/pulmonary dysfunction post-HSCT (Approved) Status note Commercial product.
Vyxeos
Approved · Active Modality: liposomal daunorubicin and cytarabine
Target DNA / topoisomerase II (daunorubicin + cytarabine, liposomal)
Indications Newly diagnosed therapy-related AML; AML with myelodysplasia-related changes (Approved) Status note Commercial product; PALOMA cooperative group study in high-risk MDS ongoing.
JZP815
Phase 1 · Active Modality: pan-RAF kinase inhibitor
Target RAF; RAS
Partnerships Redx (acquired)
Indications RAF and RAS mutant tumors (Phase 1) Status note Phase 1 ongoing.
JZP898
Phase 1 · Active Modality: conditionally-activated interferon alpha INDUKINE
Aliases WTX-613
Target IFN-alpha
Partnerships Werewolf Therapeutics (all rights acquired May 2026)
Indications renal cell carcinoma (Phase 1) urothelial carcinoma (Phase 1) melanoma (with pembrolizumab) (Phase 1) Status note Phase 1 ongoing.
JZP053
Preclinical · Active Modality: selective small-molecule Kv7.2/Kv7.3 activator
Aliases SAN2355
Target Kv7.2; Kv7.3
Partnerships Saniona (global license)
Status note Preclinical.
JZP047
Preclinical · Active
Indications absence epilepsy (Preclinical) Status note Preclinical.
JZP3507
Phase 1/2 · Active
Aliases ONC206
Partnerships Chimerix (acquired April 2025)
Indications Primary CNS tumors (Phase 1) Diffuse midline gliomas (Phase 1) Pheochromocytoma/paraganglioma (Phase 2) Meningioma (Phase 2) Status note Also known as ONC206 (acquired from Chimerix). Phase 1 in primary CNS tumors and diffuse midline gliomas (UCSF collaboration); Phase 2 in pheochromocytoma/paraganglioma (ongoing); meningioma trial initiated per Q2 2026 10-Q. Target/modality not stated in filings.
JZP3508
Preclinical · Active
Aliases ONC212
Partnerships Chimerix (acquired April 2025)
Status note Also known as ONC212 (acquired from Chimerix). Preclinical oncology; target/modality not stated in filings.
KRAS inhibitor targets
Preclinical · Active
Target G12D selective and pan-KRAS
Partnerships Redx Pharma plc (acquired)
Status note 10-K pipeline table: 'KRAS inhibitor targets | G12D selective and pan-KRAS molecules (acquired from Redx)'. No JZP designation in the filing.
Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline Lead drug Cannabidiol Lead indication Lennox Gastaut Syndrome Lead phase Phase 4 Active trials 25 Collaborator trials 36
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT05152147 Phase 3 Active, not recruiting Sponsor JAZZ — Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma — NCT07625280 Phase 3 Recruiting Sponsor JAZZ — Narcolepsy; Idiopathic Hypersomnia — NCT06435429 Phase 3 Recruiting Sponsor JAZZ — Metastatic HER2-positive Breast Cancer 3Q26 NCT05580562 Phase 3 Recruiting Sponsor JAZZ — H3 K27M; Glioma — NCT07723963 Phase 3 Not yet recruiting Sponsor JAZZ — Juvenile Myoclonic Epilepsy — NCT06282575 Phase 3 Recruiting Sponsor JAZZ — Biliary Tract Cancer — NCT07723976 Phase 3 Not yet recruiting Sponsor JAZZ — Developmental and Epileptic Encephalopathy (DEE) — NCT06695845 Phase 2 Recruiting Sponsor JAZZ — Breast Cancer; Gastric Cancer; Esophageal Cancer — NCT07102381 Phase 2 Recruiting Sponsor JAZZ — HER2-positive Breast Cancer; Breast Cancer 3Q26 NCT05734066 Phase 2 Recruiting Sponsor JAZZ — Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma; Ewing Sarcoma — NCT07459634 Phase 2 Recruiting Sponsor JAZZ — Extensive-stage Small-cell Lung Cancer — NCT07533942 Phase 2 Recruiting Sponsor JAZZ — Meningioma —
Sponsor-matched active trials from ClinicalTrials.gov (25 as sponsor, 36 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 61 active trials for Jazz Pharmaceuticals on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.